{"filing":{"accession_number":"0001801170-26-000229","cik":"0001801170","ticker":"CLOV","company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-22","primary_document":"clov-20260922.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1801170/000180117026000229/clov-20260922.htm"},"events":[{"id":34929,"run_id":32161,"accession_number":"0001801170-26-000229","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of two directors to Clover Health's Board: Senator Robert G. Torricelli (Class I director, Audit Committee) and Dr. Brian J. Miller (Class III director, Clinical Committee), effective September 22, 2026. These appointments fill two previously disclosed vacancies and bring the Board to nine directors. While the disclosure also mentions compensatory arrangements (pro-rata retainer and $200,000 RSU awards), the principal disclosed action is the appointment of these two individuals to board positions, making exec_appointment the most salient classification.","company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38812,"accession_number":"0001801170-26-000229","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two directors to Clover Health's Board: Senator Robert G. Torricelli (Class I director, Audit Committee) and Dr. Brian J. Miller (Class III director, Clinical Committee), effective September 22, 2026. These appointments fill two previously disclosed vacancies and bring the Board to nine directors. While the disclosure also mentions compensatory arrangements (pro-rata retainer and $200,000 RSU awards), the principal disclosed action is the appointment of these two individuals to board positions, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:35:20.410447+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38812,"accession_number":"0001801170-26-000229","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two directors to Clover Health's Board: Senator Robert G. Torricelli (Class I director, Audit Committee) and Dr. Brian J. Miller (Class III director, Clinical Committee), effective September 22, 2026. These appointments fill two previously disclosed vacancies and bring the Board to nine directors. While the disclosure also mentions compensatory arrangements (pro-rata retainer and $200,000 RSU awards), the principal disclosed action is the appointment of these two individuals to board positions, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:35:20.410447+00:00","company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","filing_date":"2026-09-24"}]}